Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.

Author:

Verschraegen Claire F.1,Chen Franklin2,Spigel David R.3,Iannotti Nicholas4,McClay Edward Francis5,Redfern Charles H.6,Bennouna Jaafar7,Taylor Matthew H.8,Kaufman Howard9,Kelly Karen10,Bajars Marcis11,von Heydebreck Anja12,Cuillerot Jean-Marie13,Jerusalem Guy Heinrich Maria14

Affiliation:

1. University of Vermont, Burlington, VT;

2. Novant Health Oncology Specialists, Winston-Salem, NC;

3. Sarah Cannon Research Institute, Tennessee Oncology, LLC, North Nashville, TN;

4. Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, FL;

5. California Cancer Associates for Research & Excellence, Encinitas, CA;

6. Sharp Healthcare, San Diego, CA;

7. Institut de Cancérologie de l'Ouest - site René Gauducheau, Saint Herblain, France;

8. Knight Cancer Institute, Oregon Health and Science University, Portland, OR;

9. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;

10. UC Davis Comprehensive Cancer Center, Sacramento, CA;

11. EMD Serono, Inc., Billerica, MA;

12. Merck KGaA, Darmstadt, Germany;

13. EMD Serono, Billerica, MA;

14. CHU Sart-Tilman Liege and Liege University, Liege, Belgium;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3